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Abstract—An association between increased plasma fibrinogen and an increased risk for myocardial infarction (MI) is well
established, but the nature of this association is subject to debate. Our aim was to shed light on the potentially causal
nature of this association. We examined whether increased plasma fibrinogen, due to a condition that is independent of
cardiovascular events, also increases the risk for MI. A case-control study was performed in 139 subjects with a history
of MI and 287 control subjects selected from the Rotterdam Study, a population-based cohort of 7983 subjects aged 55
years and older. The genotype of the 2455G/A polymorphism in the fibrinogen b-gene was determined by polymerase
chain reaction. Functional plasma fibrinogen levels were determined according to von Clauss. The plasma level of
fibrinogen was significantly higher in subjects with one or two A alleles compared with subjects with the GG genotype:
3.8 (95% confidence interval [CI], 3.6 to 3.9) g/L and 3.6 (3.5 to 3.7) g/L, respectively. With increasing plasma
fibrinogen level, the risk for MI increased gradually; a rise in fibrinogen of 1 g/L was associated with a 45% increased
risk (odds ratio adjusted for age, sex, and smoking, 1.45; 95% CI, 1.12 to 1.88). There was no association between the
genotype of the 2455G/A polymorphism and the risk for MI. The 2455G/A polymorphism is therefore associated with
increased plasma fibrinogen levels but not with an increased risk for MI. These findings indicate that an increased
plasma fibrinogen level due to this genetic factor does not increase the risk for MI. (Arterioscler Thromb Vasc Biol.
1998;18:621-625.)
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High plasma fibrinogen levels are associated with anincreased risk for myocardial infarction (MI).1–3 To date,
it is not clear whether an elevated plasma fibrinogen level
itself increases the risk for MI (risk factor) or whether the
elevated level is merely a reflection of the presence of
preclinical atherosclerosis or of an association with a true risk
factor (risk indicator).
Fibrinogen is related to both preclinical atherosclerosis and
to most of the cardiovascular risk factors. To elucidate
whether high plasma fibrinogen per se increases the risk for
MI, one should study the association of fibrinogen, increased
due to a factor not related to MI, with the risk for MI. When
such an “independently” raised fibrinogen level is associated
with an increased risk for MI, then this indicates that plasma
fibrinogen is causally related to the risk for MI. Unfortu-
nately, no intervention to influence plasma fibrinogen level
specifically is known. Drugs known to influence fibrinogen
levels, such as fibric acid derivatives, also alter many other
factors related to the risk of MI.4
An alternative approach is to study genetic markers that are
associated with elevated fibrinogen levels. Several poly-
morphisms in the genes for fibrinogen have been associated
with increased plasma fibrinogen, such as the 2455G/A
polymorphism.5 An individual’s genetic status is changed
neither by the presence of disease nor by risk factors for the
disease. Therefore, we presume that a genetically determined
increase in fibrinogen level is independent of other factors
related to MI. We propose that if a certain genotype for
fibrinogen is associated with an increased plasma fibrinogen
level and this increased plasma fibrinogen level causes an
increased risk for MI, then that genotype should also be
associated with an increased risk for MI.
The A allele of the 2455G/A polymorphism in the b-fibrin-
ogen gene has been associated with increased levels of plasma
fibrinogen.6 Whether possession of the A allele is associated with
an increased risk for MI is not clear. In two studies, the
2455G/A polymorphism was not associated with the risk for
MI, but the authors reported that bias in selection of subjects or
the weak association between genotype and plasma fibrinogen
level might explain the absence of an association.7,8
The present study was conducted to explore whether the A
allele of the 2455G/A polymorphism in the fibrinogen
Received February 5, 1996; revision accepted November 25, 1997.
From the Department of Epidemiology and Biostatistics and the Netherlands Institute for Health Sciences, Erasmus University Medical School,
Rotterdam (J.G. van der B., M.L.B., P.T.V.M. de J., A.H., D.E.G.); the Gaubius Laboratory, TNO-PG, Leiden (J.G. van der B., M.P.M. de M., F.H., C.K.);
the Julius Center for Patient-Oriented Research, Utrecht University, Utrecht (J.G. van der B., M.L.B., D.E.G.); the Netherlands Ophthalmic Research
Institute, Amsterdam (P.T.V.M. de J.); and the Department of Ophthalmology, Academic Medical Centre, Amsterdam (P.T.V.M. de J.), the Netherlands.
Correspondence to Prof D.E. Grobbee, Julius Center for Patient-Oriented Research, PO Box 80035, 3508 TA Utrecht, the Netherlands.
© 1998 American Heart Association, Inc.
621
b-gene is associated with raised fibrinogen levels on the one
hand and with an increased risk for MI on the other.
Methods
Population
A cross-sectional, case-control study was performed among subjects
selected from the Rotterdam Study. The Rotterdam Study is a
prospective population-based study of 7983 subjects. Between
March 1990 and July 1993, all subjects aged 55 years and older
living in Ommoord, a suburb of Rotterdam, the Netherlands, were
invited to participate. The overall response rate was 78%. The study
was approved by the Medical Ethics Committee of Erasmus Univer-
sity, and written, informed consent was obtained from all partici-
pants. The rationale and design of the study have been described
elsewhere.9
Cases (n5150) were selected from the cohort on the basis of the
presence of an infarction pattern on the electrocardiogram (ECG) and
using the diagnostic classification system of the modular ECG
analysis system,10,11 independent of a history of chest pain. Two
control subjects per case were drawn from the same 5-year age
stratum wherefrom the cases of MI were drawn, and these control
subjects constituted a sample of study participants who had no
history of cardiovascular disease, ie, no history of MI, angina
pectoris, stroke, or abnormal ECG and no peripheral arterial disease
(ankle/arm index.0.9). We excluded subjects who were using
anticoagulant drugs.
Measurements
All subjects were first visited at their home. Information on current
health status, medical history, drug use, and smoking behavior was
obtained by a computerized questionnaire, which included the Dutch
version of the Rose cardiovascular questionnaire.12 The home inter-
view was followed by two visits at the research center. Subjects were
not asked to fast or to refrain from smoking. During the clinic visits,
several cardiovascular risk indicators were determined. Height and
weight were measured, and body mass index was calculated as
weight in kilograms divided by the square of height in meters
squared. Sitting blood pressure was measured at the right upper arm
with a random-zero sphygmomanometer. The average of two mea-
surements obtained on one occasion was used. Systolic blood
pressure at the ankles (posterior tibial artery) was measured with an
8-MHz Doppler transducer while the subject was in the supine
position with an adult-size regular cuff just above the malleoli.13 The
ankle/arm index is the ratio of the systolic blood pressure at the ankle
to that at the arm. Peripheral arterial disease was defined as a right
or left ankle/arm index #0.9. Blood sampling and storage have been
described elsewhere.14 Blood samples were collected in evacuated
tubes containing CTAD (Vacutainers; 0.11 mol/L citrate, 15 mmol/L
theophylline, 3.7 mmol/L adenosine, and 0.198 mmol/L dipyridam-
ole; Diatube H, Becton-Dickinson).15 Fibrinogen was measured as
described by von Clauss.16 The 2455G/A polymorphism restriction
fragment length polymorphism of the fibrinogen b-gene was deter-
mined by amplification of the polymorphic region by polymerase
chain reaction, followed by digestion with the restriction enzyme
HaeIII as described by Thomas et al.6
Statistical Analysis
Means and proportions of cardiovascular risk factors for men and
women were calculated. Because homozygosity for the A allele was
rare and heterozygosity for the 2455G/A polymorphism was also
associated with increased levels of fibrinogen, we combined both
genotypes into one group. Subjects with a genetically increased
fibrinogen level, ie, those possessing one or two A alleles, were
categorized as the exposed group and compared with those homozy-
gous for the G allele (G/G genotype; the nonexposed group).
We examined whether increased plasma fibrinogen level was a
risk indicator in our study by comparing the risk for MI for different
levels of fibrinogen by using a logistic regression model with
fibrinogen level as a continuous variable. The number of cases and
control subjects for the exposed and nonexposed groups were
determined, and logistic regression was used to calculate the relative
risk (estimated as the odds ratio) for MI in the exposed compared
with the nonexposed group. To examine the presence of confounding
in the study population, we compared means and proportions of
cardiovascular risk factors for exposed and nonexposed subjects.
Differences were tested with Student’s ttest and Pearson’s x2 test.
Additional adjustments for the established cardiovascular disease
risk factors that might confound the association were made by adding
them to the logistic model.
To examine the potentially modifying effects of age, sex, smoking
behavior, body mass index, serum total and HDL cholesterol, and
systolic and diastolic blood pressure on the association between the
2455G/A polymorphism and the risk for MI, we stratified the study
population of men and women by age categories (cutpoint at 75
years); in current smokers (subjects who answered the question “Do
you smoke?” with “yes”) versus nonsmokers (former and never-
smokers); and according to increasing levels of body mass index
(cutpoints at 25 and 27 kg/m2), systolic blood pressure (cutpoints at
130 and 145 mm Hg), total cholesterol (cutpoints at 5.5 and
7.0 mmol/L), and HDL cholesterol (cutpoints at 1.0 and
1.5 mmol/L).
Results
After exclusion of those with missing data, the remaining
study population consisted of 139 cases and 287 control
subjects. General characteristics are presented in Table 1. The
frequency of the A allele was .20, and the distribution of the
genotypes was in Hardy-Weinberg equilibrium in both cases
and control groups.
Plasma fibrinogen level was higher in the subjects carrying
one or two A alleles compared with those homozygous for the
TABLE 1. Baseline Characteristics of the Study Population
Men Women
n 189 237
Age, y 70 (8) 74 (9)
Systolic blood pressure, mm Hg 137 (21) 142 (12)
Diastolic blood pressure, mm Hg 74 (12) 74 (12)
Body mass index, kg/m2 26 (2.7) 27 (4.2)
Current smoking, % 28 13
Total cholesterol, mmol/L 6.30 (1.11) 6.63 (1.13)
HDL cholesterol, mmol/L 1.25 (0.34) 1.42 (0.35)
Fibrinogen, g/L 3.57 (0.83) 3.72 (0.84)
Values are percentages or means and SDs.
TABLE 2. Plasma Fibrinogen (g/L) in the GG and the GA1AA
Genotypes for Cases, Control Subjects, Current Smokers, and
Noncurrent Smokers
GG GA1AA P
Cases of myocardial
infarction* 3.83 (3.65, 4.01) 3.82 (3.59, 4.05) .94
Control subjects* 3.47 (3.36, 3.58) 3.72 (3.57, 3.87) .009
Current smokers† 3.97 (3.70, 4.24) 3.96 (3.65, 4.28) .79
Noncurrent smokers† 3.50 (3.40, 3.60) 3.71 (3.57, 3.84) .02
GG5homozygous for the G allele; GA1AA5carriers of the A allele.
*Values are means and (95% confidence intervals) adjusted for age, sex, and
smoking.
†Values are means and (95% confidence intervals) adjusted for age, sex,
and case/control status.
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G allele: 3.8 g/L (95% confidence interval [CI], 3.6 to 3.9)
and 3.6 (3.5 to 3.7), respectively. The association between
fibrinogen and the presence of the A allele was restricted to
control subjects and nonsmokers (Table 2). Fibrinogen level
was associated with the risk for MI; this risk increased by
45% for each 1 g/L increase in fibrinogen level (odds ratio,
1.45; 95% CI, 1.12 to 1.88).
Among the 139 cases, 86 subjects (62%) were homozygous
for the G allele. Similarly, among the 287 control subjects,
183 subjects (64%) were homozygous for the G allele. The
risk for MI was not different for A allele carriers compared
with non–A allele carriers (Table 3). To check whether the
genetic status was associated with other cardiovascular dis-
ease risk factors (confounders), we compared these risk
factors across genetic categories (Table 4). The G/G genotype
was associated with somewhat higher total serum cholesterol
levels, higher HDL cholesterol levels, and possibly also with
a lower proportion of smokers and a somewhat higher
systolic and diastolic blood pressure. Additional adjustments
for smoking behavior, total and HDL cholesterol, and systolic
and diastolic blood pressure did not substantially change the
association between the polymorphism and the risk for MI
(Table 3).
Because the association between the presence of the A
allele and plasma fibrinogen level was restricted to nonsmok-
ers, we examined the association between the presence of the
A allele and MI in nonsmokers (102 cases and 241 control
subjects). The association did not substantially differ from the
overall results: odds ratio after adjustment for age and sex,
0.93; 95% CI, 0.56 to 1.53.
No evidence for an effect modification of the association
between the 2455G/A polymorphism and the risk for MI by
age, sex, body mass index, serum total cholesterol, serum
HDL cholesterol, systolic blood pressure, or diastolic blood
pressure was observed. Results for age, sex, and smoking
behavior are presented in Table 5.
Discussion
The main finding of this study is that the A allele of the
2455G/A polymorphism in the fibrinogen b-gene was found
to be associated with increased plasma fibrinogen but not
with an increased risk for nonfatal MI.
To appreciate these findings, some aspects of the study
design need to be discussed. To address our etiologic ques-
tion, we performed a population-based, case-control study.
Cases of nonfatal MI and control subjects were drawn from
one large, single-center study. All subjects participating in the
study were white, and allele frequencies were similar to those
reported by others.6 The observed distribution of genotypes
was identical to the expected distribution (Hardy-Weinberg
equilibrium) in cases as well as control subjects. Also, allele
frequencies for each genotype were similar in case and
control groups. This confirms that case and control subjects
originated from the same source population and provides
support for the absence of an association between the
2455G/A polymorphism and MI. A source of bias in a
cross-sectional design might be that the risk profile of cases
has changed after their MI. Because the aim of the present
study was primarily to investigate the influence of possession
of the A allele on the risk for MI, this potential source of bias
does not play a role. Plasma fibrinogen level may be different
after an MI, but genotypes are not changed by an infarct.
Finally, by virtue of its design, a cross-sectional study is
limited to nonfatal cases of MI. If the A allele were associated
with an increased proportion of fatal cases of MI, then we
would underestimate the true risk for MI associated with
possession of the A allele. To examine whether the A allele is
associated with an increased proportion of fatal cases of MI,
a longitudinal study is needed.
TABLE 3. Relative Risk (Odds Ratios and 95% Confidence
Intervals [CIs]) for Myocardial Infarction Associated With the
GA and AA Genotypes Compared With the GG Genotype
Relative Risk 95% CI
Crude risk 1.08 (0.71, 1.65)
Adjusted for age and sex 1.01 (0.66, 1.55)
Adjusted for age, sex, and smoking 0.95 (0.62, 1.47)
Adjusted for all of the above and HDL
cholesterol 0.87 (0.55, 1.35)
Adjusted for all of the above and
systolic and diastolic blood pressure 0.97 (0.61, 1.52)
TABLE 4. Means and Proportions of Cardiovascular Disease
Risk Factors for the Different Genotypes
GG GA1AA P
n 269 157
Age, y 71.2 (0.5) 73.0 (0.7) .14
Women, % 58 50 .16
Systolic blood pressure, mm Hg 140 (1.3) 138 (1.7) .19
Diastolic blood pressure, mm Hg 74 (0.7) 73 (0.9) .20
Body mass index, kg/m2 26.4 (0.2) 26.4 (0.3) .93
Current smoking, % 17 22 .18
Total cholesterol, mmol/L 6.53 (0.07) 6.40 (0.09) .26
HDL cholesterol, mmol/L 1.38 (0.02) 1.31 (0.03) .04
Fibrinogen, g/L 3.59 (0.05) 3.76 (0.07) .03
GG5homozygous for the G allele; GA1AA5heterozygous or homozygous for
the A allele.
Values are percentages or means and (SEs).
Adjusted for case/control status and when appropriate, for age and sex.
TABLE 5. Risk for Myocardial Infarction (Odds Ratio Adjusted
for Age and Sex) for the GA and AA Genotypes Compared With
the GG Genotype, Stratified for Age, Sex, and Smoking Behavior
Group
Relative Risk for
Myocardial
Infarction 95% CI
All study participants 1.01 0.66, 1.55
Age ,75 years 0.80 0.47, 1.36
Age .75 years 1.31 0.69, 2.50
Men 0.85 0.48, 1.50
Women 1.09 0.61, 1.97
Smokers 1.01 0.42, 2.41
Nonsmokers 0.94 0.59, 1.50
van der Bom et al April 1998 623
Assessment of causality of the association between fibrin-
ogen and risk for MI has been difficult. Fibrinogen, as an
acute-phase protein, is strongly associated with (preclinical)
atherosclerosis and also with a number of cardiovascular risk
factors, notably smoking.17–19 Therefore the link between
fibrinogen and cardiovascular events may have been due to
the association of fibrinogen with these other factors. Exam-
ining the association between a determinant of fibrinogen that
is independent of these other factors and the risk for MI
provides an estimate of the association between fibrinogen
and MI that is unbiased with respect to the other determinants
of fibrinogen. Our “independent determinant” of plasma
fibrinogen was the 2455G/A polymorphism. Nevertheless,
the question remains whether fibrinogen measurement with
the clotting rate–based method as described by von Clauss is
specific enough to determine the association between plasma
fibrinogen and the risk for MI. At least three molecular forms
of fibrinogen have been identified, which may have different
effects on the risk for MI.20 Recent studies on fibrates and
ticlopidine have shown reductions in fibrinogen, as measured
with a functional clotting rate–based method, but unchanged
fibrinogen molecular mass values.21 We cannot exclude
the possibility that the increase in fibrinogen level due to the
2455G/A polymorphism reflects a form other than the
“risk-carrying” form of fibrinogen.
Quantitative studies in humans are, by their nature, limited
in precision, and it is never possible to achieve the degree of
control possible in a laboratory. Perhaps the most persuasive
evidence to support a judgment of a cause-effect relationship
arises when a number of studies show similar results. The
association between the 2455G/A polymorphism and MI has
been studied in two other studies.5,7,8 In both studies, this
polymorphism was associated with plasma fibrinogen levels
but not with the risk for MI. Results of these studies are
presented in Table 6. Thus, although it is difficult to prove the
absence of an association, three studies that show the same
absence of association suggest that an increased fibrinogen
level due to the presence of the A allele is truly not associated
with the risk for MI.
Stratified analyses did not support the presence of
modification of the strength of the (absent) association for
any of the factors mentioned. It remains possible that some
unknown factor modifies the effect of possession of the A
allele on the risk for MI. Still, one expects an overall trend
to an increase in risk for MI. As the risk for nonfatal MI
did not even tend to be increased in the A allele carriers, we
presume that possession of the A allele is not associated
with an increased risk for nonfatal MI.
The association between the 2455G/A polymorphism and
plasma fibrinogen was not found in current smokers, nor in
cases with a history of MI. A possible explanation for this is
that in smokers and in cases, other factors increase the
fibrinogen level and thereby obscure the contribution of the A
allele. In the ECTIM Study, the association between the
2455G/A polymorphism and fibrinogen level was, however,
more pronounced in smokers and in cases.5 A difference
between the ECTIM Study and our study is that in our study,
smoking status and fibrinogen level were assessed at the same
time, whereas in the ECTIM Study, blood samples were taken
3 to 9 months after the MI and cigarette consumption was
defined as the daily consumption just before the event.
For clinical practice the question of causality is important.
The role of fibrinogen as an indicator for an increased risk for
MI is well established. Our finding suggests that directly
lowering fibrinogen levels may not decrease the risk for MI.
Increased plasma fibrinogen level may, however, change
after reductions in risk by other measures.
In conclusion, the finding that, in our population of men
and women aged 55 years and over, the A allele of the
2455G/A polymorphism in the fibrinogen b-gene is associ-
ated with increased plasma fibrinogen levels but not with an
increased risk for MI does not support the view that this
increased plasma fibrinogen level is causally related to the
risk for MI.
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